Remicade (infliximab) - J&J
Humira (adalimumab) - AbbVie
Stelara (ustekinumab) - J&J
Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim
Simponi (golimumab) - J&J
Entyvio (vedolizumab) - Takeda
Adherence to advanced therapies in inflammatory bowel diseases: Real-world rates and predictors of non-adherence. (PubMed, Dig Liver Dis) - Oct 10, 2026 - "Our study found a low non-adherence rate for biological and small molecule therapies in IBD patients. Higher education level and subcutaneous treatment emerged as potential risk factors for non-adherence." 
Journal • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
http://www.ncbi.nlm.nih.gov/pubmed/42855374
 
Basile Luca; Calabrese Emma; Colella Alice; Cuccagna Elisa; De Cristofaro Elena; Doni Laura; Lucarelli Michele; Marafini Irene; Monteleone Giovanni; Zorzi Francesca
 
Oct 10, 2026
 
Prev Next